Trial Profile
A Pivotal, Open-label Trial Assessing the Safety and Efficacy of the 0.5 mg Dutasteride and 0.4 mg Tamsulosin Combination Once Daily for Six Months in Patients With Benign Prostatic Hyperplasia
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Dutasteride/tamsulosin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Adverse reactions; Therapeutic Use
- Acronyms FDC114785
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 16 Dec 2015 Trial focus has been changed from AR to TU+AR and endpoints has been added related to TU as reported by ClinicalTrials.gov record.
- 21 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.